OptoSeeker Biotech and MGI Forge Strategic Partnership to Build an Autonomous, AI-Driven Antibody Discovery Platform

On August 12, 2025, Zhuoguang Biotechnology (Shenzhen) Co., Ltd. ("Zhuoguang Bio" for short) and MGI announced a strategic partnership. This collaboration will fully leverage the technical and platform advantages of both parties in the life sciences field to jointly create a workflow covering "screening-sequencing-data analysis."Full-process autonomous and controllable antibody discovery platform, accelerating the industrialization process of life science instruments.

Zhuoguang Biotechnology (Shenzhen) Co., Ltd. is an innovative life sciences company dedicated to transforming new drug discovery. It develops cutting-edge life science instruments to accelerate biological research and development. The company owns a proprietary single-cell functional screening platform capable of precisely identifying and isolating the most therapeutically promising "seed" antibody cells from tens of thousands of cells.

MGI, as a provider of core tools in life science, focuses on the research and development of underlying technologies and product innovation for the core tools based on the "reading, writing, and storing" principles of the central dogma of life. It continuously offers users systematic solutions that cover all scenarios and the entire lifecycle in life science research and applications. MGI has not only achieved a comprehensive strategic layout for gene sequencing products across three technical pathways—"excited light," "self-luminous," and "non-luminous"—but is also the world's first company to simultaneously possess commercially mass-producible short-read and long-read sequencing products.

Focusing on the cutting-edge demands of the domestic market, both parties will closely cooperate to further drive the breakthrough of core bottlenecks in antibody drug development, significantly...ShortenAntibody DiscoveryCycle`, providing original innovative impetus to overcome major diseases affecting national health.`

Dr. Xie Hainan (left), CEO of Zhuoguang Biotechnology (Shenzhen) Co., Ltd., and Mr. Liu Jian (right), Executive Vice President of MGI, sign the cooperation agreement on behalf of both parties.

Dr. Xie Hainan, CEO of Zhuoguang Biotechnology (Shenzhen) Co., Ltd., stated: "We are very proud to join hands with MGI, the leader in China's sequencing industry. This cooperation is not only a partnership at the business level but also a significant collaboration for China."Collaborative Development of Local Innovative Forces"A powerful proof, perfectly aligning with the national strategy to build a strong and self-reliant health industry. This collaboration fully demonstrates our determination and capability to create world-class technology in China."

MGI's Executive Vice President, Jian Liu, stated: "As the 'Creator of Core Tools for Life Science,' MGI is committed to providing advanced equipment platforms and an open ecosystem for users worldwide. We look forward to collaborating with Zhuoguang Biotechnology to jointly explore a new ecosystem for drug discovery that is rooted locally and benefits the globe."

It is worth mentioning that the cooperation between Zhuoguang Biotechnology and MGI will further synergize with AI pharmaceutical company BioMap. Through the large foundational life science model constructed by BioMap, it will enhance Zhuoguang Biotechnology's OptoBot.^®Massive single-cell functional data and corresponding sequencing fusion data generated on the series product platformIn-depth Analysis, therebyPredict, Design, and OptimizeMore clinically promising antibody drugs, forming a "led by Chinese companies"Screening"—Sequencing—AI-Powered"A new generation of drug R&D closed-loop system.

OptoBot^®Product Series

The full-chain platform collaboratively built by Zhuoguang Biotechnology, MGI, and BioMap has demonstrated a comprehensive breakthrough in drug discovery capabilities from key technologies to system integration, which will help China's drug research and development system move towards a new stage of comprehensive independence and intelligence-driven development.

About Zhuoguang Biotechnology (OptoSeeker Biotech) 

Zhuoguang Biotechnology (Shenzhen) Co., Ltd. is an innovative Chinese life sciences company dedicated to transforming drug discovery, focusing on developing cutting-edge life science instruments to accelerate biological research and development.

We have an independently developed platform that deeply integrates core technologies such as optoelectronic tweezers, microfluidics, biochips, fluorescence staining, and protein labeling to provide ultra-high throughput functional single-cell screening and rapidly identify high-value cells for antibody and cell therapy development. We are committed to enhancing China's biopharmaceutical R&D capabilities and contributing Chinese strength to accelerating the birth of innovative drugs.

About MGI (MGI) 

MGI Tech Co., Ltd. (referred to as MGI) adheres to the concept of "Innovative Manufacturing Leading Life Science" and focuses on the field of life.The core tool underlying technology R&D and product innovation of the "Read, Write, Store" principle continuously provides users with systematic solutions covering all scenarios and the entire life cycle in life science research and applications. It is committed to promoting breakthroughs in scientific research directions and clinical application transformation with multi-omics technologies centered on gene sequencing technology, while collaborating with upstream and downstream sectors of the life science and biotechnology industries to build an open, cooperative, and win-win industrial ecosystem.

MGI was founded in 2016. As of December 31, 2024, its business operations have expanded to over 110 countries and regions across six continents. Globally, MGI has established 9 major R&D centers, 7 production bases, 9 international warehouses, and 13 customer experience centers, serving more than 3,300 cumulative users. As a provider of core tools in life science, MGI has achieved a comprehensive strategic layout for gene sequencing products based on three technological approaches: "excitation light," "self-emission," and "non-emission." Moreover, MGI is the world's first company to simultaneously possess commercially mass-producible short-read and long-read sequencing products.

About BioMap (BioMap) 

BioMap is a global pioneer in foundational large models for life sciences. Its 210-billion-parameter biolanguage large model decodes the underlying principles of genomes, proteins, cells, and biological systems, serving as a "biological simulator" that significantly reduces reliance on traditional experimental models, empowering research and development.

Currently, BioMap has achieved State-of-the-Art (SOTA) performance in over 200 tasks across drug discovery, biomanufacturing, fundamental research, and healthcare. It provides large model-driven professional AI Agents to more than 700 global customers in dozens of specialized subfields, integrating data, models, and experimental capabilities to deliver cutting-edge applications such as advanced drug discovery, improved bio-reaction efficiency, biological data interpretation, and knowledge acquisition.